

Yu-Fang Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4230674/publications.pdf>

Version: 2024-02-01

28
papers

894
citations

516215

16
h-index

525886

27
g-index

28
all docs

28
docs citations

28
times ranked

1560
citing authors

#	ARTICLE	IF	CITATIONS
1	FOXO1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. <i>Oncotarget</i> , 2015, 6, 2349-2365.	0.8	128
2	EGF upregulates Na ⁺ /H ⁺ exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness. <i>Journal of Cellular Physiology</i> , 2008, 214, 810-819.	2.0	86
3	COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBP β pathway and PDK1 stabilization. <i>Oncotarget</i> , 2015, 6, 23748-23763.	0.8	84
4	Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF κ B-mediated IKK β expression. <i>International Journal of Cancer</i> , 2017, 141, 2305-2317.	2.3	53
5	Cell fate regulation by gelsolin in human gynecologic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14442-14447.	3.3	52
6	All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells. <i>Carcinogenesis</i> , 2015, 36, 498-507.	1.3	52
7	COL11A1 activates cancer-associated fibroblasts by modulating TGF- β 3 through the NF κ B/IGFBP2 axis in ovarian cancer cells. <i>Oncogene</i> , 2021, 40, 4503-4519.	2.6	45
8	Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression. <i>Cell Death and Disease</i> , 2019, 10, 322.	2.7	42
9	Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e69.	1.0	40
10	Violet Laser Diode Enables Lighting Communication. <i>Scientific Reports</i> , 2017, 7, 10469.	1.6	36
11	Current state of evidence-based practice education for undergraduate nursing students in Taiwan: A questionnaire study. <i>Nurse Education Today</i> , 2015, 35, 1262-1267.	1.4	35
12	Circulating IGF system and treatment outcome in epithelial ovarian cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 217-229.	1.6	34
13	<i>Solanum Incanum</i> Extract Downregulates Aldehyde Dehydrogenase 1-Mediated Stemness and Inhibits Tumor Formation in Ovarian Cancer Cells. <i>Journal of Cancer</i> , 2015, 6, 1011-1019.	1.2	31
14	Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 206.	1.6	29
15	A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 437.	1.3	23
16	Primary Treatment and Prognostic Factors of Carcinosarcoma of the Ovary, Fallopian Tube, and Peritoneum: A Taiwanese Gynecologic Oncology Group Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 506-512.	1.2	20
17	Brain metastases from epithelial ovarian carcinoma: Evaluation of prognosis and managements – A Taiwanese Gynecologic Oncology Group (TGOG) Study. <i>Gynecologic Oncology</i> , 2012, 125, 37-41.	0.6	16
18	Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy. <i>Pharmaceuticals</i> , 2021, 14, 549.	1.7	15

#	ARTICLE	IF	CITATIONS
19	miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by Inhibiting COL11A1. <i>Cancers</i> , 2021, 13, 6257.	1.7	12
20	Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix. <i>BMC Women's Health</i> , 2017, 17, 56.	0.8	11
21	Three-dimensional power doppler ultrasound is useful to monitor the response to treatment in a patient with primary papillary serous carcinoma of the peritoneum. <i>Ultrasound in Medicine and Biology</i> , 2006, 32, 623-626.	0.7	10
22	Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study. <i>European Journal of Cancer</i> , 2014, 50, 3161-3167.	1.3	8
23	Vitamin D Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription. <i>Clinical Cancer Research</i> , 2018, 24, 3217-3228.	3.2	8
24	Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1095.	1.3	8
25	Prenatal diagnosis of radial agenesis in trisomy 18 using three-dimensional ultrasound. <i>Prenatal Diagnosis</i> , 2004, 24, 923-924.	1.1	7
26	Seeking new surgical predictors of mesh exposure after transvaginal mesh repair. <i>International Urogynecology Journal</i> , 2016, 27, 1547-1555.	0.7	7
27	Abstract 958: Activation of COL11A1 by anticancer drugs through IGF-1R/PI3K pathway confers chemoresistance in ovarian cancer via activating NF- κ B-mediated Twist1 expression. , 2014, , .		1
28	Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study. <i>Cancers</i> , 2022, 14, 1746.	1.7	1